Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

IGF-1 DES vs Hulk Stack

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than Hulk Stack (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

IGF-1 DES

Anecdotal + Animal Studies

Hulk Stack

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

IGF-1 DES Hulk Stack
Class IGF-1 analog (truncated); anabolic GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation.
Route SC / IM SC injection (typically 2-3 separate sites)
Half-life ~30 min CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs
Dosage (research) 50-150 mcg SC near target muscle Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks
Evidence tier Anecdotal + Animal Studies Anecdotal
Research depth 25 indexed (PubMed 13 · CT 0 · EPMC 12) —
Availability Research Chemical Compounding Restricted
Reported risks Hypoglycemia; localized tissue growth; theoretical cancer risk Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick IGF-1 DES or Hulk Stack?

IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than Hulk Stack (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between IGF-1 DES and Hulk Stack?

IGF-1 DES is classed as IGF-1 analog (truncated); anabolic; Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: IGF-1 DES, ~30 min; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: IGF-1 DES, SC / IM; Hulk Stack, SC injection (typically 2-3 separate sites).

Which has stronger evidence, IGF-1 DES or Hulk Stack?

IGF-1 DES and Hulk Stack sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.

Which is more accessible, IGF-1 DES or Hulk Stack?

Neither IGF-1 DES nor Hulk Stack is an FDA-approved drug. Catalog status: IGF-1 DES, Research Chemical; Hulk Stack, Compounding Restricted.

Are IGF-1 DES and Hulk Stack ever combined?

IGF-1 DES and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…